The Efficacy of Phosphodiesterase-5 Inhibitors on Pulmonary Vascular Resistance in Patients with Single Ventricle Physiology
Keywords:
Single Ventricle Physiology, Fontan Operation, Phosphodiesterase-5 Inhibitors, Sildenafil, Pulmonary Vascular Resistance, HemodynamicsAbstract
Introduction: Patients with single ventricle physiology often undergo the Fontan procedure, creating a circulation highly dependent on low pulmonary vascular resistance (PVR) for long-term success. Phosphodiesterase-5 (PDE-5) inhibitors are used as targeted pulmonary vasodilators to improve these hemodynamics. This systematic review aims to evaluate the efficacy of PDE-5 inhibitors on PVR and associated clinical outcomes in this specific patient population. Methods: Following the PRISMA 2020 guidelines, a comprehensive search was conducted across multiple databases, including PubMed and Google Scholar, using PICO-based keywords. Eligibility screening of abstracts and full-text articles was performed to include randomized controlled trials and cohort studies. After a rigorous selection process, 34 relevant studies were included in the final qualitative synthesis. Results: The analysis revealed consistent hemodynamic improvements. A significant reduction in PVR or its related indices was explicitly reported in 11 studies , while 20 studies noted a decrease in pulmonary artery pressure. These benefits translated to improved clinical outcomes, with 11 studies demonstrating enhanced exercise capacity and 13 studies reporting increased oxygen saturation. The safety profile was highly favorable, as 25 studies reported no significant adverse events. However, significant statistical heterogeneity was detected among studies (I²=94%). Conclusion: PDE-5 inhibitors are a safe and effective therapy for improving short-term hemodynamics, exercise capacity, and oxygenation in patients with single ventricle physiology. While the evidence strongly supports their use, it is limited by substantial heterogeneity and a lack of long-term data. Large-scale, standardized randomized controlled trials are imperative to establish definitive long-term benefits and formulate optimal clinical guidelines.
References
A. Awad, Eman Reda Gad, M. S. Abdelgalil, A. Elsaeidy, O. Ahmed, and M. Elbadawy. “Sildenafil for Congenital Heart Diseases Induced Pulmonary Hypertension, a Meta-Analysis of Randomized Controlled Trials.” BMC Pediatrics, 2023.
A. Giardini, A. Balducci, S. Specchia, G. Gargiulo, M. Bonvicini, and F. Picchio. “Effect of Sildenafil on Haemodynamic Response to Exercise and Exercise Capacity in Fontan Patients.” European Heart Journal, 2008.
A. Hager, S. Fratz, and J. Hess. “Effect of Sildenafil on Haemodynamic Response to Exercise and Exercise Capacity in Fontan Patients.” European Heart Journal, 2008.
A. Van de Bruaene, A. La Gerche, G. Claessen, P. De Meester, S. Devroe, H. Gillijns, J. Bogaert, et al. “Sildenafil Improves Exercise Hemodynamics in Fontan Patients.” Circulation Cardiovascular Imaging, 2014.
Anuja Gupta, and P. Kerkar. “Sildenafil for Pulmonary Hypertension Secondary to Congenital Heart Dis- eases.” Indian Heart Journal, 2007.
B. Castaldi, Giulia Bordin, M. Padalino, E. Cuppini, V. Vida, and O. Milanesi. “Hemodynamic Impact of Pulmonary Vasodilators on Single Ventricle Physiology.” Cardiovascular Therapeutics, 2018.
D. Goldberg, B. French, M. Mcbride, B. Marino, Nicole Mirarchi, B. Hanna, G. Wernovsky, S. Paridon, and J. Rychik. “Impact of Oral Sildenafil on Exercise Performance in Children and Young Adults After the Fontan Operation: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.” Circulation, 2011.
D. Goldberg, V. Zak, Bryan H. Goldstein, K. Schumacher, J. Rhodes, D. Penny, Christopher J. Petit, et al. “Results of the FUEL Trial.” Circulation, 2019.
D. Goldberg, V. Zak, Bryan H. Goldstein, Shan Chen, M. Hamstra, E. Radojewski, E. Maunsell, et al. “Abstract 14024: Results of a Phase I / II Multicenter Investigation of Udenafil in Adolescents After Fontan Palliation.” Circulation, 2015.
E. Levunlieva, A. Kaneva, R. Lekova, K. Nenova-Karakasheva, and L. Dimitrov. “Invasive Hemodynamic Assessment of the Effect of Sildenafil Treatment After Fontan Operation.” Bulgarian Cardiology, 2022.
Gira S. Morchi, D. Ivy, M. Duster, L. Claussen, Kak-Chen Chan, and Joseph D. Kay. “Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology.” Congenital Heart Disease, 2009.
I. Palii, E. Vataman, N. Revenco, L. Maniuc, M. Vătăman, and O. Repin. “O-024 Outcome Research In 77 Patients With Pulmonary Arterial Hypertension Receiving Sildenafil: A Double-Blind, Randomised Controlled Study.” Archives of Disease in Childhood, 2014.
I. Palii, E. Vataman, and P. Stratulat. “Efficacy of Sildenafil Therapy in Children with Pulmonary Hyper- tension Secondary to Congenital Systemic-to-Pulmonary Shunts,” 2013.
Jiawang Zhou, Y. Lyu, Yuzhen Jia, and Zhen-dong Hu. “Effect of Sildenafil in the Treatment of Hypoxemia After Operation of Cyanotic Congenital Heart Disease,” 2015.
Jigisha Pujara, Sunny Kesvani, Pragya Sachan, Bhavik Champaneri, Garima Harbola, Ryan Vachaparamil, Tanya Chhauda, and Deepika Gehlot. “Intravenous Sildenafil for Perioperative Management of Patients with Pulmonary Artery Hypertension in Congenital Heart Surgery − a Prospective Randomized Study.” The Egyptian Journal of Cardiothoracic Anesthesia, 2021.
Jonathan B Edelson, V. Zak, David J. Goldberg, Greg Fleming, Andrew S. Mackie, J. K. Patel, Matthew D. Files, et al. “The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation.” American Journal of Cardiology, 2023.
K. Hill, Robert D. Tunks, P. Barker, D. Benjamin, M. Cohen-Wolkowiez, Gregory A. Fleming, M. Laughon, and Jennifer S. Li. “Sildenafil Exposure and Hemodynamic Effect After Stage II Single-Ventricle Surgery.” Pediatric Critical Care Medicine, 2013.
Long Xiang-pen. “The Effect of Sildenafil to Pulmonary Hypertension with Congenital Heart Disease in Children,” 2009.
M. Alipour, M. H. Lookzade, F. Motahari, and M. Nemayande. “Assessing the Efficacy of Tadalafil in Reducing Pulmonary Hypertension in Children and Adolescents Aged 5 Months-15 Years,” 2015.
Mariana M. Clavé, N. Maeda, A. Thomaz, S. Bydlowski, and A. Lopes. “Phosphodiesterase Type 5 In- hibitors Improve Microvascular Dysfunction Markers in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.” Congenital Heart Disease, 2018.
Michael V. Di Maria, David J. Goldberg, S. Paridon, A. Lubert, A. Dragulescu, Andrew S. Mackie, Andrew McCrary, et al. “Abstract 13502: Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in Fuel Study Participants.” Circulation, 2020.
P. Ciliberti, and A. Giardini. “Impact of Oral Chronic Administration of Sildenafil in Children and Young Adults After the Fontan Operation.” Future Cardiology, 2011.
P. Namachivayam, U. Theilen, S. Cooper, W. Butt, D. Penny, and L. Shekerdemian. “Abstract 2033: Sildenafil Prevents Rebound Pulmonary Hypertension After Discontinuation of Inhaled Nitric Oxide: A Randomized, Double-Blind Placebo-Controlled Study in Children,” 2006.
P. Namachivayam, U. Theilen, W. Butt, Sian M. Cooper, D. Penny, and L. Shekerdemian. “Sildenafil Prevents Rebound Pulmonary Hypertension After Withdrawal of Nitric Oxide in Children.” American Journal of Respiratory and Critical Care Medicine, 2006.
Pang Yu-sheng. “Short Term Efficacy and Safety of Sildenafil Treatment for Pre-or Post-Opertative Pul- monary Arterial Hypertension in Children with Congenital Heart Disease:a Systematic Review,” 2011.
R. Giordano, G. Palma, V. Poli, S. Palumbo, V. Russolillo, S. Cioffi, M. Mucerino, V. Mannacio, and C. Vosa. “First Experience with Sildenafil After Fontan Operation: Short-Term Outcomes.” Journal of Cardiovascular Medicine, 2015.
Robert D. Tunks, P. Barker, D. Benjamin, M. Cohen-Wolkowiez, Gregory A. Fleming, M. Laughon, Jennifer S. Li, and K. Hill. “Sildenafil Exposure and Hemodynamic Effect After Fontan Surgery.” Pediatric Critical Care Medicine, 2014.
S. Menon, Richard V Willimas, E. Saarel, Amanda Grove, C. Weng, and L. Minich. “Abstract 16024: Effect of Tadalafil on Exercise Parameters in Young Fontan Patients,” 2013.
Van De Bruane, A. Gerche, G. Claessen, P. Meester, S. Devroe, Jan Bogaert, Piet Claus, Hein Heidbuchel, M. Gewillig, and Werner Budts. “Sildenafil Improves Exercise Hemodynamics in Fontan Patients,” 2013. Xian-ling Lu, C. Xiong, G. Shan, Xian-Yang Zhu, Bingxiang Wu, Guang-hua Wu, Zhi-Hong Liu, et al. “Impact of Sildenafil Therapy on Pulmonary Arterial Hypertension in Adults with Congenital Heart Disease.” Cardiovascular Therapeutics, 2010.
Yusuf Ananda Fikri, E. P. B. Mulia, and Faris Wahyu Nugroho. “Preoperative Sildenafil in Pediatric Patients Undergoing Congenital Heart Surgeries: A Systematic Review and Meta-Analysis.” Seminars in Cardiothoracic and Vascular Anesthesia, 2023.
Z. Khajali, M. Peighambari, S. Lotfian, Maryam Golari, Bahar Galeshi, M. Rouhani, and Zahra Alizadeh. “Tadalafil and Exercise Capacity After Fontan Operation,” 2018.
Zhang Chen. “The Effects of Sildenafil in Children with Pulmonary Arterial Hypertension Due to Congenital Heart Disease,” 2011.
Zhou Jiawang, Lv Yong, Hu Zhendong, Qiu Zongli, P. Ran, and X. Yibai. “Sildenafil in the Treatment of Postoperative Hypoxemia with High Resistance in Cyanotic Congenital Heart Disease,” 2017.
Published
Issue
Section
License
Copyright (c) 2025 Rhinza Seputra Simanjuntak, Miftah Pramudyo, Frisky Ronald Tua Marbun, Rheza Felari Simanjuntak, Tatyana Sianipar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
